Table 1. Patients characteristics (n = 55).
| N | % | |
|---|---|---|
| Age(y) | ||
| Median (range) | 55(31–77) | |
| Gender | ||
| Female | 32 | 58.2 |
| Male | 23 | 41.8 |
| Smoking history | ||
| Never-Smoker | 44 | 80.0 |
| Former/smoker | 11 | 20.0 |
| Pathology | ||
| Adenocarcinoma | 53 | 96.4 |
| squamous cell carcinoma | 2 | 3.6 |
| EGFR mutation status | ||
| Exon 19 deletion | 23 | 41.8 |
| Exon 21 L858R | 20 | 36.4 |
| Wild type | 4 | 7.3 |
| Unknown | 8 | 14.5 |
| Disease stage | ||
| Stage IV | 43 | 78.2 |
| Recurrent | 12 | 21.8 |
| Initiation of EGFR-TKI | ||
| 1st line | 30 | 54.5 |
| 2/3rd line | 25 | 45.5 |
| TKI regimen choice | ||
| Erlotinib | 37 | 67.3 |
| Gefitinib/Icotinib | 18 | 32.7 |
| Local therapy | ||
| No | 36 | 65.5 |
| Yes | 19 | 34.5 |
| Site of RECIST PD | ||
| Lung | 44 | 80.0 |
| Bone | 4 | 7.3 |
| Brain | 4 | 7.3 |
| Lymph node | 1 | 1.8 |
| Visceral (liver, adrenal gland) | 2 | 3.6 |
| Progression type | ||
| Local progression | 10 | 18.2 |
| Slow/Minimal progression | 45 | 81.8 |
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; RECIST, Response Evaluation Criteria in Solid Tumors; PD, progression disease.